Tag Archives: GNFTF

Top 10 Undervalued Stocks To Own For 2019

&l;p&g;&l;img class=&q;dam-image bloomberg size-large wp-image-42435712&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/42435712/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Bloomberg

The NASDAQ is generally not thought of as home sweet home for value stocks. Typically, if you&s;re looking at a NASDAQ situation, you&s;re looking for growth.&a;nbsp; But if you&s;re willing to take a deep dive sometimes you can find interesting potential candidates just under the growth-oriented surface. Are companies trading there which might still be thought of as &q;undervalued?&q;

I found this group that might fit by screening for those with price/earnings ratios of below 15 and which are trading for less than book value. Anything that failed to show positive earnings over the past half-decade is ignored. With all of that in mind and acknowledging that there may be significant issues underlying such stocks, here&s;s the list of those that fit the basic requirements:

Top 10 Undervalued Stocks To Own For 2019: PDC Energy, Inc.(PDCE)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on PDC Energy (PDCE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    News articles about PDC Energy (NASDAQ:PDCE) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PDC Energy earned a news impact score of 0.12 on Accern’s scale. Accern also gave news articles about the energy producer an impact score of 46.6251700229584 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on PDC Energy (PDCE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Undervalued Stocks To Own For 2019: Genfit SA (GNFTF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.

  • [By ]

    This phase 2 data for Madrigal was phenomenal, which is why I think it will do well in a phase 3 trial. The other side of the trade is that Intercept Pharmaceuticals (ICPT) and Genfit (OTCPK:GNFTF) are further along with phase 3 trials, which are expected to read out NASH results by 2019/2020. Intercept has a good drug with Ocaliva, however, it suffers from toxicity issues when Doctors prescribe higher than necessary dosing. On the flip side, Ocaliva has shown a greater difference in fibrosis reduction for NASH in its phase 2 FLINT trial compared to MGL-3196. What do I mean by that? Well, as you can see above MGL-3196 obtained a fibrosis reduction in NASH patients of 29% compared to 23% for those on placebo creating a difference of only 6%. If you look at Ocaliva from the FLINT trial, from Intercept Pharmaceuticals, it had a fibrosis reduction of 35% compared to 19% of those NASH patients on placebo. It is just something to keep in mind. I still believe that MGL-3196 will eventually be approved. The question that should be asked is how well will it do compared to other competitors in the same space with better fibrosis reductions? That will be key, because NASH causes fibrosis (scarring) of the liver. Fibrosis eventually turns into cirrhosis of the liver, which can eventually lead to liver failure. That’s why, in my opinion, a drug that will have the most impact on NASH will be one that shows a major reduction in fibrosis. The good news is that the NASH market is expected to reach between $20 to $30 billion in the coming years. It is a large market for plenty of players in this space. The other endpoints are important as well, but in a competitive market such as NASH, fibrosis reduction will make the difference in terms of more sales. This is just an important factor to keep in mind.

  • [By ]

    Heres what we wrote: With GR-MD-02, Galectin is also targeting a different spectrum of NASH. The companys programs with GR-MD-02 are focusing on NASH treatment in individuals with advanced fibrosis and cirrhosis. As we mentioned before, Genfit (OTCPK:GNFTF) and Intercept (ICPT) are targeting what can be termed as the sweet spot of the NASH spectrum. Galecctin is one of the few companies targeting advanced stage of the disease. This makes it both an interesting and at the same time risky bet in the NASH space.

Top 10 Undervalued Stocks To Own For 2019: Cabot Microelectronics Corporation(CCMP)

Advisors’ Opinion:

  • [By Max Byerly]

    Shares of Cabot Microelectronics Co. (NASDAQ:CCMP) have received a consensus recommendation of “Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $114.80.

  • [By Ethan Ryder]

    Shares of Cabot Microelectronics Co. (NASDAQ:CCMP) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $112.25.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Cabot Microelectronics (CCMP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Cabot Microelectronics (NASDAQ: CCMP) and Analog Devices (NASDAQ:ADI) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

  • [By Joseph Griffin]

    News coverage about Cabot Microelectronics (NASDAQ:CCMP) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cabot Microelectronics earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave news stories about the semiconductor company an impact score of 46.640513544039 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Top 10 Undervalued Stocks To Own For 2019: Templeton Dragon Fund Inc.(TDF)

Advisors’ Opinion:

  • [By Shane Hupp]

    Templeton Dragon Fund Inc common stock (NYSE:TDF) major shareholder City Of London Investment Grou bought 8,155 shares of the company’s stock in a transaction that occurred on Tuesday, June 12th. The shares were purchased at an average price of $22.87 per share, with a total value of $186,504.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Top 10 Undervalued Stocks To Own For 2019: Forward Pharma A/S(FWP)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Forward Pharma A/S (NASDAQ: FWP) shares gained 88.18 percent to close at $4.14 on Tuesday.
    Regional Health Properties, Inc. (NYSE: RHE) shares jumped 18.04 percent to close at $0.3010 on Tuesday.
    Precipio, Inc. (NASDAQ: PRPO) shares gained 16.61 percent to close at $0.49 after the nano-cap specialty diagnostics company said it saw an acceleration of sales in its Pathology services in April. The company now expects to see a sequential double digit quarterly sales growth.
    Arcturus Therapeutics Ltd. (NASDAQ: ARCT) rose 16.09 percent to close at $7.00 on Tuesday.
    America's Car-Mart, Inc. (NASDAQ: CRMT) gained 14.53 percent to close at $62.65 after reporting upbeat Q4 results.
    NanoString Technologies, Inc. (NASDAQ: NSTG) shares surged 12.64 percent to close at $13.19.
    Geron Corporation (NASDAQ: GERN) gained 12.12 percent to close at $4.07 on Tuesday.
    Quotient Limited (NASDAQ: QTNT) shares climbed 11.58 percent to close at $6.55 on Tuesday.
    American Equity Investment Life Holding Company (NYSE: AEL) rose 11.23 percent to close at $32.28 following a report from Reuters that the company is looking for a sale.
    iQIYI, Inc. (NASDAQ: IQ) gained 11.15 percent to close at $22.52.
    Veracyte, Inc. (NASDAQ: VCYT) rose 10.4 percent to close at $7.11.
    Stein Mart, Inc. (NASDAQ: SMRT) gained 10.26 percent to close at $3.33. Stein Mart is expected to release quarterly earnings on May 23.
    MiMedx Group, Inc. (NASDAQ: MDXG) shares rose 10.11 percent to close at $8.06.
    The Container Store Group, Inc. (NYSE: TCS) gained 8.2 percent to close at $8.18. Container Store reported weaker-than-expected earnings for its fourth quarter after the closing bell.
    Photronics, Inc. (NASDAQ: PLAB) shares gained 7.69 percent to close at $9.10 after the company reported upbeat Q2 results.
    Micron Technology, Inc. (NASDAQ: MU) rose 6.4 percent to close at $59.03 after reporting a $10 billion buyback plan.

     

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Forward Pharma A/S (NASDAQ: FWP) fell 15.2 percent to $3.51 in pre-market trading after surging 88.18 percent on Tuesday.
    Pfenex Inc. (NASDAQ: PFNX) shares fell 15 percent to $5.85 in pre-market trading after the company announced an offering of common stock.
    Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) fell 17.6 percent to $47.75 in pre-market trading after the company reported downbeat results for its first quarter and issued a weak earnings forecast for the second quarter.
    Container Store Group, Inc. (NYSE: TCS) fell 13 percent to $7.15 in pre-market trading after reporting weaker-than-expected earnings for its fourth quarter.
    Ardelyx, Inc. (NASDAQ: ARDX) shares fell 12.1 percent to $4.00 in pre-market trading after reporting pricing of public offering of common stock.
    Boston Scientific Corporation (NYSE: BSX) shares fell 9.8 percent to $27.31 in pre-market trading.
    Turkcell Iletisim Hizmetleri A.S. (NYSE: TKC) fell 6.5 percent to $6.60 in pre-market trading.
    Target Corporation (NYSE: TGT) shares fell 5.8 percent to $71.02 in pre-market trading. Target reported weaker-than-expected earnings for its first quarter, while sales exceeded estimates.
    PBF Energy Inc. (NYSE: PBF) shares fell 5.7 percent to $42.42 in pre-market trading

Top 10 Undervalued Stocks To Own For 2019: Microsoft Corporation(MSFT)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    Earnings season is well underway. And if you’re looking to make real money, the time to get started is now. Money MorningQuantitative Specialist Chris Johnson argues the markets are at a tipping point. And with just a few smart plays in today’s classic stock picker’s market… you can pull in triple-digit gains with just a small investment. Read those picks right here.

    The Top Stock Market Stories for Thursday
    This morning, the U.S. Department of Labor said that weekly jobless claims came in at 207,000 for the week. That figure is below the 220,000 jobless claims expected by economists and brings U.S. unemployment claims to a 48.5-year low. It’s a big day of earnings reports, as dozens of blue chip companies will report results from the June-ending quarter. The biggest name today will be Microsoft Corp.(Nasdaq: MSFT), which reports earnings after the bell. Wall Street expects that the technology giant will report earnings of $1.07 per share. Analysts project quarterly revenue of $29.17 billion.
    Three Stocks to Watch Today: PM, IBM, AA
    International Business Machines (NYSE: IBM) stock added 2.5% in pre-market hours after Big Blue topped Wall Street earnings and revenue expectations. The tech giant continues to post positive results as it accelerates its turnaround efforts. IBM reported earnings per share of $3.08, a figure that beat estimates by $0.04 per share. It also reported quarterly revenue of $20.0 billion, a figure that surpassed estimates of $19.85 billion. Shares of Alcoa Corp. (NYSE: AA) fell 2% this morning. The aluminum manufacturer slashed its 2018 outlook due to falling prices and the recent round of metals tariffs introduced by the Trump administration. But there could be more pain in sight. Today, the U.S. Justice Department will hold a hearing that aims to determine whether vehicle and light truck imports present a national security threat to the United States. The hearing is due to President Trump’s pledge to hit European auto man

  • [By Money Morning News Team]

    This ETF holds shares of 30 stocks that are major players in the cloud computing market. Chief among them is Amazon.com Inc. (Nasdaq: AMZN), who leads all other cloud services with its AWS service. Another is Microsoft Corp. (Nasdaq: MSFT), whose Azure cloud service is now the second largest of its kind in the world.

  • [By Max Byerly]

    Microsoft (NASDAQ:MSFT) has been given a $125.00 target price by analysts at Credit Suisse Group in a research report issued on Friday. The firm currently has a “buy” rating on the software giant’s stock. Credit Suisse Group’s price objective suggests a potential upside of 17.62% from the company’s previous close.

  • [By Chuck Saletta]

    As Amazon CEO Jeff Bezos famously said, “Your margin is my opportunity.”Amazon’s own margin is coming from computing services — an area where it faces stiff competition from the likes of Microsoft (NASDAQ:MSFT). Microsoft is no stranger to aggressive competitive practices, and it doesn’t have to support a massive retail business with the revenue from cloud computing.

  • [By JJ Kinahan]

    In addition to reports from T and VZ, these are some of the other major companies reporting earnings this week:

    Caterpillar Inc. (NYSE: CAT) and Eli Lilly and Co. (NYSE: LLY) report before market open on Tuesday, Apr. 24
    Boeing Co (NYSE: BA) reports before the open on Wednesday, Apr. 25
    Twitter Inc. (NYSE: TWTR) reports before the open Wednesday, Apr. 25 and Facebook, Inc. (NASDAQ: FB) reports after the close the same day
    Ford Motor Company (NYSE: F) reports after market close Wednesday, Apr. 25 and General Motors Company (NYSE: GM) reports before the open Thursday, Apr. 26
    Amazon.com, Inc. (NASDAQ: AMZN), Intel Corporation (NASDAQ: INTC) and Microsoft Corporation (NASDAQ: MSFT) all report after market close Thursday, Apr. 26
    Chevron Corporation (NYSE: CVX) and Exxon Mobil Corporation (NYSE: XOM) report before the open Friday, Apr. 27

    Information from TDA is not intended to be investment advice or construed as a recommendation or endorsement of any particular investment or investment strategy, and is for illustrative purposes only. Be sure to understand all risks involved with each strategy, including commission costs, before attempting to place any trade.

  • [By WWW.GURUFOCUS.COM]

    For the details of Milestone Resources Group Ltd’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Milestone+Resources+Group+Ltd

    These are the top 5 holdings of Milestone Resources Group LtdAccenture PLC (ACN) – 762,770 shares, 13.26% of the total portfolio. Microsoft Corp (MSFT) – 1,100,825 shares, 11.54% of the total portfolio. Shares reduced by 8.69%Alphabet Inc (GOOGL) – 92,032 shares, 11.04% of the total portfolio. Shares reduced by 9.52%S&P Global Inc (SPGI) – 463,802 shares, 10.05% of the total portfolio. Zoetis Inc (ZTS) – 1,065,914 shares, 9.6

Top 10 Undervalued Stocks To Own For 2019: Pain Therapeutics(PTIE)

Advisors’ Opinion:

  • [By Chris Lange]

    Pain Therapeutics Inc. (NASDAQ: PTIE) shares were destroyed on Wednesday after a vote from the U.S. Food and Drug Administration (FDA) was announced. As we have said before, the FDA has the potential to make or break biopharmaceutical companies. In this case, Pain Therapeutics has been broken.

  • [By Brian Orelli]

    DURECT Corp. (NASDAQ:DRRX) is down 9.2% at 12:45 p.m. EDT after the U.S. Food and Drug Administration’s advisory committee voted14 to 3 recommending the agency not approve Remoxy ER, an abuse-deterrent extended-release pain medication being developed by its partner Pain Therapeutics(NASDAQ: PTIE).

  • [By Peter Graham]

    Small cap pain stock Pain Therapeutics (NASDAQ: PTIE) has elevated short interest of 35.77% according to Highshortinterest.com. Pain Therapeuticsdevelops proprietary drugs that offer significant improvements to patients and physicians.The Companysexpertise consists of developing new drugs and guiding these through various regulatory and development pathways in preparation for their eventual commercialization with a focuson drug development efforts around disorders of the nervous system.The FDA has not yet established the safety or efficacy ofany drug candidates. Pain Therapeuticspipeline of drug assets includes:

Top 10 Undervalued Stocks To Own For 2019: International Speedway Corporation(ISCA)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    International Speedway Corporation (NASDAQ: ISCA)Q2 2018 Earnings Conference callJul. 05, 2018, 1:00 pm ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on International Speedway Corp Class A (ISCA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on International Speedway Corp Class A (ISCA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Undervalued Stocks To Own For 2019: BHP Billiton plc(BBL)

Advisors’ Opinion:

  • [By Max Byerly]

    Shares of BHP Billiton plc (NYSE:BBL) gapped down before the market opened on Thursday . The stock had previously closed at $43.47, but opened at $43.83. BHP Billiton shares last traded at $44.17, with a volume of 117112 shares.

  • [By Max Byerly]

    Natixis Advisors L.P. raised its position in shares of BHP Billiton plc (NYSE:BBL) by 10.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,996 shares of the mining company’s stock after purchasing an additional 1,113 shares during the quarter. Natixis Advisors L.P.’s holdings in BHP Billiton were worth $477,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Hallador Energy (NASDAQ: HNRG) and BHP Billiton (NYSE:BBL) are both oils/energy companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Top 10 Undervalued Stocks To Own For 2019: VALE S.A.(VALE)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of Vale SA (NYSE:VALE) gapped down before the market opened on Monday . The stock had previously closed at $13.11, but opened at $12.82. Vale shares last traded at $12.49, with a volume of 13924600 shares.

  • [By Joseph Griffin]

    Westwood Holdings Group Inc. purchased a new position in Vale SA (NYSE:VALE) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,796 shares of the basic materials company’s stock, valued at approximately $150,000.

  • [By Billy Duberstein]

    Wheaton’s new streaming deal is with Brazilian miner Vale (NYSE:VALE)at its Voisey Bay nickel mine in Newfoundland, Canada. Wheaton, along with smaller Canadian streaming company Cobalt 27 Capital Corp., will invest a combined $690 million in Vale’s $1.7 billion expansion of the mine. Vale’s initial plans have been delayed since last August, when the price of nickel declined; however, thanks to Wheaton and Cobalt 27, the mine will be expanded and will begin producing cobalt by 2021.

  • [By Stephan Byrd]

    State of New Jersey Common Pension Fund D increased its stake in shares of Vale (NYSE:VALE) by 12.4% in the first quarter, HoldingsChannel reports. The firm owned 781,510 shares of the basic materials company’s stock after buying an additional 86,443 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Vale were worth $9,941,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Rational Advisors LLC grew its position in Vale SA (NYSE:VALE) by 49.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,951 shares of the basic materials company’s stock after acquiring an additional 4,951 shares during the period. Rational Advisors LLC’s holdings in Vale were worth $191,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    Brookfield Asset Management Inc. purchased a new position in shares of Vale SA (NYSE:VALE) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 40,493 shares of the basic materials company’s stock, valued at approximately $515,000.

Top Growth Stocks To Buy Right Now

Netflix Inc. (NASDAQ: NFLX) reported first-quarter financial results after markets closed Monday. The company said that it had $0.64 in earnings per share (EPS) on $3.70 billion in revenue, compared with consensus estimates from Thomson Reuters that called for $0.64 in EPS on $3.69 billion in revenue. The same period of last year had $0.40 in EPS on $2.64 billion in revenue.

During the first quarter, global net adds totaled a new first-quarter record of 7.41 million, up 50% year over year and ahead of the firms 6.35 million forecast. In the United States, Netflix added 1.96 million memberships (compared with a forecast of 1.45 million). Internationally, the firm added 5.46 million memberships.

Note that Netflix now has a total of 125 million total memberships worldwide.

Netflix completed its price adjustment during this past quarter, resulting in 12% average selling price growth for the domestic segment. Another highlight from this report is that the international segment now accounts for 50% of revenue and 55% of memberships.

Top Growth Stocks To Buy Right Now: Curtiss-Wright Corporation(CW)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Curtiss-Wright (NYSE:CW) declared a quarterly dividend on Wednesday, May 16th, RTT News reports. Shareholders of record on Thursday, June 21st will be paid a dividend of 0.15 per share by the aerospace company on Thursday, July 5th. This represents a $0.60 annualized dividend and a yield of 0.46%.

  • [By Max Byerly]

    Dynamic Technology Lab Private Ltd decreased its stake in shares of Curtiss-Wright Corp. (NYSE:CW) by 59.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,188 shares of the aerospace company’s stock after selling 4,625 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Curtiss-Wright were worth $430,000 at the end of the most recent quarter.

Top Growth Stocks To Buy Right Now: Yingli Green Energy Holding Company Limited(YGE)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Yingli Green Energy Holding Co Ltd (NYSE:YGE) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $1.40 and last traded at $1.53, with a volume of 75280 shares. The stock had previously closed at $1.57.

  • [By Logan Wallace]

    ValuEngine upgraded shares of Yingli (NYSE:YGE) from a sell rating to a hold rating in a report published on Saturday morning.

    Yingli stock opened at $1.60 on Friday. The company has a market capitalization of $30.36 million, a PE ratio of -0.17 and a beta of 1.98. Yingli has a twelve month low of $1.43 and a twelve month high of $2.86. The company has a quick ratio of 0.33, a current ratio of 0.40 and a debt-to-equity ratio of -0.11.

  • [By Joseph Griffin]

    Yingli Green Energy (NYSE:YGE) had its target price raised by S&P Equity Research from $0.45 to $0.62 in a research report released on Tuesday morning.

  • [By Ethan Ryder]

    Yingli Green Energy (NYSE: YGE) and Netlist (NASDAQ:NLST) are both small-cap oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

  • [By Paul Ausick]

    Yingli Green Energy Holding Co. Ltd. (NYSE: YGE) slipped about 1.2% to post a new 52-week low of $1.68 Friday after closing at $1.70 on Thursday. The 52-week high is $3.35. Volume of about 5.9 million was more than 15 times the daily average of around 88,000. The company had no specific news.

Top Growth Stocks To Buy Right Now: Genfit SA (GNFTF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.

  • [By ]

    This phase 2 data for Madrigal was phenomenal, which is why I think it will do well in a phase 3 trial. The other side of the trade is that Intercept Pharmaceuticals (ICPT) and Genfit (OTCPK:GNFTF) are further along with phase 3 trials, which are expected to read out NASH results by 2019/2020. Intercept has a good drug with Ocaliva, however, it suffers from toxicity issues when Doctors prescribe higher than necessary dosing. On the flip side, Ocaliva has shown a greater difference in fibrosis reduction for NASH in its phase 2 FLINT trial compared to MGL-3196. What do I mean by that? Well, as you can see above MGL-3196 obtained a fibrosis reduction in NASH patients of 29% compared to 23% for those on placebo creating a difference of only 6%. If you look at Ocaliva from the FLINT trial, from Intercept Pharmaceuticals, it had a fibrosis reduction of 35% compared to 19% of those NASH patients on placebo. It is just something to keep in mind. I still believe that MGL-3196 will eventually be approved. The question that should be asked is how well will it do compared to other competitors in the same space with better fibrosis reductions? That will be key, because NASH causes fibrosis (scarring) of the liver. Fibrosis eventually turns into cirrhosis of the liver, which can eventually lead to liver failure. That’s why, in my opinion, a drug that will have the most impact on NASH will be one that shows a major reduction in fibrosis. The good news is that the NASH market is expected to reach between $20 to $30 billion in the coming years. It is a large market for plenty of players in this space. The other endpoints are important as well, but in a competitive market such as NASH, fibrosis reduction will make the difference in terms of more sales. This is just an important factor to keep in mind.

  • [By ]

    Heres what we wrote: With GR-MD-02, Galectin is also targeting a different spectrum of NASH. The companys programs with GR-MD-02 are focusing on NASH treatment in individuals with advanced fibrosis and cirrhosis. As we mentioned before, Genfit (OTCPK:GNFTF) and Intercept (ICPT) are targeting what can be termed as the sweet spot of the NASH spectrum. Galecctin is one of the few companies targeting advanced stage of the disease. This makes it both an interesting and at the same time risky bet in the NASH space.

Best Bank Stocks To Invest In 2018

Retirees interested in the security of guaranteed income often turn to immediate annuities, which provide regular payments that begin right away in exchange for a lump-sum investment. In recent years, that guarantee has come at a price: Low interest rates have depressed monthly payments. But rates have begun to move up and are expected to climb higher. Annuity payouts are rising, too.

QUIZ: Are Annuities Right for You?

In October 2016, a 65-year-old man who invested $100,000 in a single-life immediate annuity would have received an average monthly payment of $506, says ImmediateAnnuities.com. The average monthly payment recently was $567, up 12%. The Federal Reserve raised the rate for overnight bank loans by 0.25 percentage point in March and signaled that it plans at least two more hikes this year. You may be inclined to postpone an annuity purchase until those hikes take effect. But if the economy falters, the Fed could put off those increases. If rates fall, youll have missed a chance to lock in current rates. One way around this problem is to build an annuity ladder. Suppose you have $200,000 to invest. Instead of investing it all at once, you might invest $50,000 this year and another $50,000 every two years until youve spent the entire amount. If rates rise, you can take advantage of them. And if rates fall, youll have locked in at least some of your money at current rates.

Best Bank Stocks To Invest In 2018: Celanese Corporation(CE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Time To Favor Optionality: Most macro data are similar to, or better than, when the merger was announced. As a result, the same returns have been obtainable, with significantly less stress, simply through owning 3M (MMM) or a basket of chemical companies that approximate the Dow-DuPont portfolio. Relative to the chemical sector, performance has been average, leverage appears reasonable but near-term FCF less-than compelling partly due to new capacity ramping. With the merger likely to close in the near-term (90% chance, in our view), we believe Dow-DuPont will have an opportunity to show how scale creates optionality. The overhaul at Celanese (CE) over the past few years shows the way.

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Albemarle Corporation (NYSE: ALB): Free Stock Analysis Report
     
    Celanese Corporation (NYSE: CE): Free Stock Analysis Report
     
    Kronos Worldwide Inc (NYSE: KRO): Free Stock Analysis Report
     
    Koppers Holdings Inc. (NYSE: KOP): Free Stock Analysis Report
     
    Chemours Company (The) (CC): Free Stock Analysis Report
     
    Kraton Corporation (NYSE: KRA): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Shane Hupp]

    Celanese (NYSE: CE) and Sealed Air (NYSE:SEE) are both basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Best Bank Stocks To Invest In 2018: Genfit SA (GNFTF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.

Best Bank Stocks To Invest In 2018: Pacific Biosciences of California Inc.(PACB)

Advisors’ Opinion:

  • [By Paul Ausick]

    Pacific Biosciences of California Inc. (NASDAQ: PACB) slipped about 5.6% to post a new 52-week low of $2.52 Tuesday after closing at $2.67 on Friday. Volume of about 910,000 was about 10% above the daily average. The company had no specific news.

Top 5 Value Stocks To Buy For 2018

Retirees can draw a crucial investment lesson from studying the two major anniversaries the market is celebrating this month.

I put celebrating in quotes because the first of those two anniversaries was the top of the Internet bubble in March 2000, 18 years ago. The bursting of that bubble is something many of us would just as soon forget, of course, since the Nasdaq Composite index
COMP, -2.43%
subsequently lost nearly 80% of its value.

Top 5 Value Stocks To Buy For 2018: Vuzix Corporation(VUZI)

Advisors’ Opinion:

  • [By William Patalon III]

    Vuzix Corp. (Nasdaq: VUZI) – the “augmented reality” company whose shares more than doubled following our September 2015 recommendation – said that its new “smart glasses” were just honored with a “Wearable Device of the Year” award.

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.

    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.

    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

Top 5 Value Stocks To Buy For 2018: Tronox Limited(TROX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Tronox Ltd (NYSE: TROX) were down 23 percent to $19.55. The FTC has challenged Tronox acquisition of Cristal’s titanium dioxide business. Tronox disclosed that it will fight FTC lawsuit seeking to block proposed acquisition of Saudi-owned Cristal.

  • [By Lisa Levin]

    Tronox Ltd (NYSE: TROX) shares shot up 34 percent to $19.30. Tronox announced plans to acquire Cristal's TiO(2) business and also agreed to sell Alkali Business. Tronox posted a Q4 loss of $0.14 per share on revenue of $548 million.

Top 5 Value Stocks To Buy For 2018: Sunoco LP(SUN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).

  • [By Douglas A. McIntyre]

    Exxon Mobil Corp. (NYSE: XOM) is the second largest company in America and the world’s largest oil company. Chevron Corp. (NYSE: CVX) is the third largest company in the United States. Valero Corp. (NYSE: VLO) is among the world’s largest refiners. Sunoco L.P. (NYSE: SUN) is one of North America’s largest owners of stations and convenience stores. BP PLC (NYSE: BP) is among the world’s oil behemoths. Shell is the U.S. branch of oil giant Royal Dutch Shell PLC (NYSE: RDS-A).

  • [By ]

    That’s the case for Sunoco (NYSE: SUN). After posting a net loss of $0.09 per share in 2017, the gas station owner is expected to swing to a hefty profit of $2.35 per share in 2018. But of the 14 analysts who follow the company, earnings estimates range as low as $1.22 and as high as $3.35 — so there is a high degree of uncertainty.

Top 5 Value Stocks To Buy For 2018: Genfit SA (GNFTF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    In a recent article, we discussed what makes Genfits (OTCPK:GNFTF) Elafibranor one of the most promising candidates in the NASH treatment development space. Given the unmet need (no approved therapies), Elafibranors mechanism of action and the potential it has shown in clinical stages, we see a strong chance of approval if the pivotal Phase 3 study succeeds. In this article, we will briefly discuss the chances of Elafibranors success in clinical stages and Genfits valuation based on the potential of its lead product candidate. We will briefly also discuss the risks to the investment thesis.

Top 5 Value Stocks To Buy For 2018: Theravance Biopharma, Inc.(TBPH)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    The exact date Theravance Biopharma Inc. (TBPH) intends to release a phase 3 update on COPD treatment Revefenacin isnt known. The company simply said in a prior communication with the market it would be sharing an interim look at the trials progress sometime in early Q4.